Welch P J, Wang J Y
Department of Biology, University of California, San Diego, La Jolla 92093-0347, USA.
Mol Cell Biol. 1995 Oct;15(10):5542-51. doi: 10.1128/MCB.15.10.5542.
The decision to enter the cell division cycle is governed by the interplay between growth activators and growth inhibitors. The retinoblastoma protein (RB) is an example of a growth inhibitor whose main function appears to be the binding and inactivation of key cell cycle activators. One target of RB is a proto-oncoprotein, the c-Abl tyrosine kinase. RB binds to the ATP-binding lobe in the kinase domain and inhibits the nuclear pool of c-Abl in quiescent and G1 cells. Phosphorylation of RB at G1/S releases c-Abl, leading to the activation of this nuclear tyrosine kinase. In this report, we describe the construction of a mutant Abl, replacing the ATP-binding lobe of c-Abl with that of c-Src. The mutant protein AS2 is active as a tyrosine kinase and can phosphorylate Abl substrates, such as the C-terminal repeated domain of RNA polymerase II. AS2, however, does not bind to RB, and its activity is not inhibited by RB. As a result, the nuclear pool of AS2 is no longer cell cycle regulated. Excess AS2, but not its kinase-defective counterpart, can overcome RB-induced growth arrest in Saos-2 cells. Interestingly, wild-type c-Abl, in both its kinase-active and -inactive forms, can also overcome RB. Furthermore, overexpression of a kinase-defective c-Abl in rodent fibroblasts accelerates the transition from quiescence to S phase and cooperates with c-Myc to induce transformation. These effects, however, do not occur with the kinase-defective form of AS2. Thus, the growth-stimulating function of the kinase-defective c-Abl is dependent on the binding and the abrogation of RB function. That RB function can be abolished by the overproduction of one of its binding proteins is consistent with the hypothesis that RB induces cell cycle arrest by acting as a "molecular matchmaker" to assemble protein complexes. Exclusive engagement of RB by one of its many targets is incompatible with the biological function of this growth suppressor protein.
细胞进入分裂周期的决定受生长激活因子和生长抑制因子之间相互作用的调控。视网膜母细胞瘤蛋白(RB)是一种生长抑制因子,其主要功能似乎是结合并使关键的细胞周期激活因子失活。RB的一个作用靶点是一种原癌蛋白,即c-Abl酪氨酸激酶。RB与激酶结构域中的ATP结合叶结合,并抑制静止期和G1期细胞中c-Abl的核内库。RB在G1/S期的磷酸化会释放c-Abl,导致这种核酪氨酸激酶的激活。在本报告中,我们描述了一种突变型Abl的构建,即将c-Abl的ATP结合叶替换为c-Src的ATP结合叶。突变蛋白AS2作为酪氨酸激酶具有活性,能够磷酸化Abl底物,如RNA聚合酶II的C末端重复结构域。然而,AS2不与RB结合,其活性也不受RB抑制。因此,AS2的核内库不再受细胞周期调控。过量的AS2而非其激酶缺陷型对应物能够克服RB诱导的Saos-2细胞生长停滞。有趣的是,野生型c-Abl,无论其激酶活性形式还是非活性形式,也都能克服RB的作用。此外,在啮齿动物成纤维细胞中过表达激酶缺陷型c-Abl会加速从静止期到S期的转变,并与c-Myc协同诱导细胞转化。然而,这些效应在激酶缺陷型AS2中并未出现。因此,激酶缺陷型c-Abl的生长刺激功能依赖于与RB的结合以及对RB功能的消除。RB功能可因其一种结合蛋白的过量表达而被消除,这与RB通过充当“分子媒人”来组装蛋白复合物从而诱导细胞周期停滞的假说相一致。RB众多靶点之一对其的独占性结合与这种生长抑制蛋白的生物学功能不相符。